Received Jan 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (NOVAVAX)) | NOVAVAX | UNK | 6315MF0013 | OT |
gave Nuvaxovid ten days after it had expired with no reported adverse event; Initial information received on 13-Jan-2026 (with live follow-up information received on 14-Jan-2026) regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 64 years old female patient who received a NVX-COV2373 (ORIGINAL) ADJUVANTED VACCINE ten days after it had expired with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 11-Jan-2026, the patient received an unknown expired dose of suspect NVX-COV2373 (ORIGINAL) ADJUVANTED VACCINE (strength, expiry date-31-DEC-2025 and lot number-6315MF0013) via unknown route in unknown administration site for Immunization for with no reported adverse event (expired product administered) (latency-same day). Reportedly- It was administered a few days ago. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.